Gout News and Research RSS Feed - Gout News and Research

Gout is a type of arthritis that causes painful inflammation in the joints. Usually it affects one joint which is most commonly the big toe. However, it can affect any joint in the body such as the ankles, knees, wrists, elbows and any joints in the hands or finger.

Symptoms of gout usually develop rapidly and usually start at night. The joint may then start to feel normal again with any pain or discomfort eventually disappearing . However, most people who get gout will have further attacks in the future.

The symptoms of gout are caused by an above normal level of urate in the bloodstream, which builds up and forms crystals, mainly in and around joints and especially in the finger and toe joints. This can lead to intensely pain and inflammation.

There are several factors that can increase the level of blood urate. These include a diet rich in purines (which form urate when broken down) such as red meat, seafood and some other foods; excess alcohol consumption; the use of certain medicines such as diuretics; a family history of gout; kidney disease; and overweight or obesity.

Gout affects about 1% of the population and is more common in men, particularly those aged 30 to 60, and in women who have already experienced the menopause.
3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio enters into exclusive license agreement with PharmAbcine for Tanibirumab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with PharmAbcine, Inc. for the development, manufacturing and marketing of Tanibirumab, an anti-VEGFR2/KDR antibody for cancer in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and several emerging countries, including Thailand, Brazil and Russia. [More]
Montmorency cherry concentrate helps reduce effects of gout

Montmorency cherry concentrate helps reduce effects of gout

Drinking Montmorency concentrate significantly helps to reduce the effects of the painful condition gout, according to new research. [More]
3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio signs exclusive license agreement with JenKem for PEG-irinotecan

3SBio Inc., a leading biotechnology company based in China focusing on researching, developing, manufacturing and marketing biopharmaceutical products, announced today that it has entered into an exclusive license agreement with JenKem Technology Co., Ltd for the development, manufacturing and marketing in Mainland China of PEG-irinotecan, a long-acting polymer-drug conjugate which inhibits topoisomerase I (Topo-I). [More]
Plant-based medication after cardiac surgery shows mixed results in reducing complications

Plant-based medication after cardiac surgery shows mixed results in reducing complications

Administration of colchicine, a plant-based medication commonly used to treat gout, before and after cardiac surgery showed mixed results in reducing potential complications from this type of surgery, but it did increase the risk of gastrointestinal adverse effects, according to a study published by JAMA. [More]
3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey). [More]
Researchers create combination drug that controls both tumor growth and metastasis

Researchers create combination drug that controls both tumor growth and metastasis

Researchers at UC Davis, University of Massachusetts and Harvard Medical School have created a combination drug that controls both tumor growth and metastasis. By combining a COX-2 inhibitor, similar to Celebrex, and an epoxide hydrolase (sEH) inhibitor, the drug controls angiogenesis (blood vessel formation), limiting a tumor's ability to grow and spread. [More]
Study reveals that inflammasomes remain active even after cell death

Study reveals that inflammasomes remain active even after cell death

Even after a cell dies, components of the immune system remain active and continue to fuel inflammatory reactions. [More]
3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis. [More]
Study supports proposal to screen all men with gout for presence of ED

Study supports proposal to screen all men with gout for presence of ED

A new study presented today at the European League Against Rheumatism Annual Congress showed that erectile dysfunction (ED) is present in most men with gout and is frequently severe. [More]
Researchers discover how uric acid helps prevent aging and disease

Researchers discover how uric acid helps prevent aging and disease

Interested in antioxidants? They protect us against aging and cancer. It's one of the reasons we like our green tea and even our broccoli. But there is a new kid on the antioxidant block - uric acid. [More]
CT scans allow rheumatologists to diagnose gout

CT scans allow rheumatologists to diagnose gout

Gout is on the rise among U.S. men and women, and this piercingly painful and most common form of inflammatory arthritis is turning out to be more complicated than had been thought. [More]
Study shows how changes in organized cell membrane network of heart muscle leads to heart failure

Study shows how changes in organized cell membrane network of heart muscle leads to heart failure

Colchicine, a drug that's used to treat gout, has the beneficial side effect of lowering the risk of heart attack in patients taking it. Conversely, taxol, a drug for treating cancer, has the opposite effect; raising the risk of heart failure. [More]
Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics reports net income of $24 million for fourth quarter 2013

Safeguard Scientifics, Inc. today announced fourth quarter and full-year 2013 financial results. For the three months ended December 31, 2013, Safeguard's net income was $24.0 million, or $1.10 per share, compared to net loss of $10.8 million, or $0.51 per share for the same period in 2012. For the year ended December 31, 2013, Safeguard's net loss was $35.5 million, or $1.66 per share, compared to $39.4 million, or $1.88 per share for the same period in 2012. [More]
Actavis files ANDA with FDA to market  Colchicine Tablets USP

Actavis files ANDA with FDA to market Colchicine Tablets USP

Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colchicine Tablets USP, 0.6 mg. [More]
Gouty tophi predict cardiovascular remodeling

Gouty tophi predict cardiovascular remodeling

Research shows that the severity of gout, rather than uric acid level, is significantly associated with changes in left ventricular diastolic function and left atrial volume. [More]
Oral ingestion of inosine compound raises urate levels, shows Parkinson's study

Oral ingestion of inosine compound raises urate levels, shows Parkinson's study

New findings published in JAMA Neurology from research into a potentially protective therapy for Parkinson's disease (PD) show that with medical supervision, urate levels may safely be raised while mitigating risk of complications such as gout. [More]

Savient gets bankruptcy court approval to sell all assets to Crealta

Savient Pharmaceuticals, Inc. announced that it has received approval from the U.S. Bankruptcy Court for the District of Delaware to sell substantially all of the assets of Savient, including all KRYSTEXXA assets, to Crealta Pharmaceuticals LLC. [More]
Crealta to acquire all assets of Savient Pharmaceuticals

Crealta to acquire all assets of Savient Pharmaceuticals

Savient Pharmaceuticals, Inc. ("Savient") announced that it has reached agreement on the terms of an acquisition agreement with Crealta Pharmaceuticals LLC ("Crealta") through which Crealta would acquire substantially all of the assets of Savient, including all KRYSTEXXA® assets, for gross proceeds of approximately $120.4 million. [More]
Researchers find evidence that gout clusters in families

Researchers find evidence that gout clusters in families

It's historically known as 'the king of diseases and the disease of kings' and was long thought to be caused by an overindulgent lifestyle, but now scientists at The University of Nottingham have confirmed that 'gout' strongly runs in families. [More]
Implantable genetic circuit serves as early warning system for high blood-fat levels

Implantable genetic circuit serves as early warning system for high blood-fat levels

Humankind has a weight problem - and not only in the industrialised nations, either: the growing prosperity in many Asian or Latin American countries goes hand in hand with a way of life that quite literally has hefty consequences. [More]